Josh Hammermesh

Josh has been Gamida Cell’s chief business officer since April 2018, applying more than two decades of experience in corporate strategy and commercialization for pharmaceutical and biotechnology companies to the role. Prior to joining Gamida Cell, Josh served as senior vice president at Locust Walk Partners, Inc., a strategic partnering and financing transaction advisory firm, where he played an instrumental role in leading numerous transactions across an array of therapeutic areas and technologies. Prior to Locust Walk, Josh served as vice president, business and corporate development at Infinity Pharmaceuticals, Inc., where he was responsible for the company’s in-licensing, out-licensing and alliance management activities. Prior to Infinity, he served as senior vice president, strategy and corporate development at Pervasis Therapeutics, Inc., where he led strategic partnering initiatives for the company’s product development portfolio.

Earlier in his career, Josh held positions at Molecular Insight Pharmaceuticals, Inc., Sanofi Genzyme and MG Biotherapeutics LLC. Josh is currently a member of the board of directors at Neurohealing Pharmaceuticals, Inc. He holds a B.S., magna cum laude, from Amherst College and an MBA from Harvard Business School.